Folate-Targeted Nanoliposomal Chemophototherapy
-
Published:2023-09-26
Issue:10
Volume:15
Page:2385
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Chitgupi Upendra1ORCID, Qin Yiru1, Ghosh Sanjana1, Quinn Breandan1, Carter Kevin1, He Xuedan1, Sunar Ulas2ORCID, Lovell Jonathan F.1ORCID
Affiliation:
1. Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA 2. Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794, USA
Abstract
Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensitive porphyrin-phospholipid (PoP) liposomes, which were assessed for FA-targeted chemophototherapy (CPT). PoP liposomes and FA-conjugated PoP liposomes were loaded with Doxorubicin (Dox), and physical properties were characterized. In vitro, FA-PoP liposomes that were incubated with FA receptor-overexpressing human KB cancer cells showed increased uptake compared to non-targeted PoP liposomes. Dox and PoP contributed towards chemophototherapy (CPT) in vitro, and PoP and FA-PoP liposomes induced cell killing. In vivo, mice bearing subcutaneous KB tumors treated with PoP or FA-PoP liposomes loaded with Dox, followed by 665 nm laser treatment, had delayed tumor growth and improved survival. Dox delivery to tumors increased following laser irradiation for both PoP and FA-PoP liposomes. Thus, while Dox-FA-PoP liposomes were effective following systemic administration and local light irradiation in this tumor model, the FA targeting moiety did not appear essential for anti-tumor responses.
Funder
National Institutes of Health National Science Foundation
Subject
Pharmaceutical Science
Reference39 articles.
1. Cervical cancer worldwide;Vu;Curr. Probl. Cancer,2018 2. Zhang, S., Cheng, C., Lin, Z., Xiao, L., Su, X., Zheng, L., Mu, Y., Liao, M., Ouyang, R., and Li, W. (2022). The global burden and associated factors of ovarian cancer in 1990–2019: Findings from the global burden of disease study 2019. BMC Public Health, 22. 3. Baydoun, M., Boidin, L., Leroux, B., Vignion-Dewalle, A.-S., Quilbe, A., Grolez, G.P., Azaïs, H., Frochot, C., Moralès, O., and Delhem, N. (2023). Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer. Int. J. Mol. Sci., 24. 4. Overexpression of folate binding protein in ovarian cancers;Toffoli;Int. J. Cancer,1997 5. The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander?;Kelemen;Int. J. Cancer,2006
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|